menu
    • menu
    [{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Vaccine","year":"2020","type":"Not Applicable","leadProduct":"AE37 Peptide","moa":"Helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Biotechnology \/ Not Applicable"},{"orgOrder":0,"company":"NuGenerex","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Financing","leadProduct":"AE37 Peptide","moa":"CD4 T-Cell","graph1":"Oncology","graph2":"Phase II","graph3":"NuGenerex","amount2":0.050000000000000003,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"NuGenerex \/ Undisclosed","highestDevelopmentStatusID":"8","companyTruncated":"NuGenerex \/ Undisclosed"},{"orgOrder":0,"company":"Generex Biotechnology","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2020","type":"Not Applicable","leadProduct":"AE37 Peptide","moa":"Helper T lymphocyte","graph1":"Oncology","graph2":"Phase II","graph3":"Generex Biotechnology","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intradermal Injection","sponsorNew":"Generex Biotechnology \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Generex Biotechnology \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for AE37 Peptide

    Menu

    AE37 Peptide

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Generex Biotechnology

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Generex Biotechnology

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AE37 Peptide,Sargramostim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            NuGenerex Immuno-Oncology Publishes Review Article on Cancer Vaccines Highlighting AE37 (Ii-Key-HER2) Immunoth...

                            Details : The paper describes why the Phase IIb clinical trial of AE37 in breast cancer demonstrated a statistically significant clinical benefit for certain subgroups of patients in the trial while failing to meet the primary endpoint in the entire intent-to-trea...

                            Brand Name : AE37

                            Molecule Type : Peptide

                            Upfront Cash : Not Applicable

                            October 13, 2020

                            Lead Product(s) : AE37 Peptide,Sargramostim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            NuGenerex

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            NuGenerex

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AE37 Peptide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            NuGenerex Immuno-Oncology Closes $50 Million Financing Facility

                            Details : NuGenerex Immuno-Oncology is developing immunotherapeutic Ii-Key peptide vaccines for cancer and infectious diseases.

                            Brand Name : AE37

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            July 15, 2020

                            Lead Product(s) : AE37 Peptide,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Undisclosed

                            Deal Size : $50.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Generex Biotechnology

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Generex Biotechnology

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : AE37 Peptide,Sargramostim

                            Therapeutic Area : Oncology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Generex Subsidiary NuGenerex Immuno-Oncology Announces Publication of Positive Results of the AE37 Phase IIb B...

                            Details : The presentation revealed AE37 Ii-Key peptide vaccine is safe and associated with DFS in sub-sets of breast cancer survivors after 10-year follow-up .

                            Brand Name : Undisclosed

                            Molecule Type : Vaccine

                            Upfront Cash : Not Applicable

                            April 28, 2020

                            Lead Product(s) : AE37 Peptide,Sargramostim

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth